Published in AIDS on April 24, 2013
Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men | NCT00458393
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science (1996) 18.38
Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell (1996) 17.81
Preexposure prophylaxis for HIV infection among African women. N Engl J Med (2012) 15.28
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01
Clinical and epidemiologic features of primary HIV infection. Ann Intern Med (1996) 6.04
Acute human immunodeficiency virus type 1 infection. N Engl J Med (1998) 5.04
Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep (2011) 4.85
Acute HIV-1 Infection. N Engl J Med (2011) 4.84
HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis (2005) 3.77
Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS (2007) 3.72
Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J Virol (1996) 3.48
Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study. PLoS One (2008) 3.40
Effect of HIV antibody disclosure on subsequent sexual activity in homosexual men. AIDS (1987) 3.01
A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis (2006) 2.88
Sexual risk behaviors and implications for secondary HIV transmission during and after HIV seroconversion. AIDS (2002) 2.33
Factors associated with prevalent human immunodeficiency virus (HIV) infection in the Multicenter AIDS Cohort Study. Am J Epidemiol (1987) 2.29
Predictors of disease progression in HIV infection: a review. AIDS Res Ther (2007) 2.05
Natural history of serum HIV-1 RNA levels in 330 patients with a known date of infection. The SEROCO Study Group. AIDS (2000) 2.04
HIV treatment as prevention and HPTN 052. Curr Opin HIV AIDS (2012) 1.97
Psychosocial predictors of reported behavior change in homosexual men at risk for AIDS. Health Educ Q (1986) 1.90
Where techno-science meets poverty: medical research and the economy of blood in The Gambia, West Africa. Soc Sci Med (2006) 1.60
Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load. J Infect Dis (2000) 1.54
Knowledge, attitudes, beliefs and motivations towards blood donations among blood donors in Lagos, Nigeria. Transfus Med (2004) 1.33
Progression of human immunodeficiency virus type 1 (HIV-1) infection among homosexual men in hepatitis B vaccine trial cohorts in Amsterdam, New York City, and San Francisco, 1978-1991. Am J Epidemiol (1994) 1.18
The time from infection with human immunodeficiency virus (HIV) to the onset of AIDS. J Infect Dis (1986) 1.05
CAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck. J Infect Dis (2012) 0.99
Early markers of HIV-1 disease progression in a prospective cohort of seroconverters in Bangkok, Thailand: implications for vaccine trials. J Acquir Immune Defic Syndr (2004) 0.92
Factors influencing HIV progression in a seroconverter cohort in Madrid from 1985 to 1999. Sex Transm Infect (2002) 0.86
Challenges in the study of patients with HIV type 1 seroconversion. Clin Infect Dis (2005) 0.85
Community mobilization for blood donation, Cross River State, Nigeria. The Calabar PMM Team. Int J Gynaecol Obstet (1997) 0.77
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19
Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med (2005) 6.02
The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol (2011) 4.18
The challenge of HIV-1 subtype diversity. N Engl J Med (2008) 3.88
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med (2013) 3.24
Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA (2006) 3.23
Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS (2009) 2.91
Combining Google Earth and GIS mapping technologies in a dengue surveillance system for developing countries. Int J Health Geogr (2009) 2.87
Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS (2005) 2.48
Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr (2005) 2.32
Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J Virol (2011) 2.26
HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS One (2009) 2.16
Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s. J Infect Dis (2007) 1.89
Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel. J Infect Dis (2012) 1.73
The development of CD4 binding site antibodies during HIV-1 infection. J Virol (2012) 1.53
Preventing HIV infection in women: a global health imperative. Clin Infect Dis (2010) 1.47
Proinflammatory cytokines in HIV disease-a review and rationale for new therapeutic approaches. AIDS Rev (2005) 1.35
Regulatory T cell suppression of Gag-specific CD8 T cell polyfunctional response after therapeutic vaccination of HIV-1-infected patients on ART. PLoS One (2010) 1.32
Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1. J Virol (2012) 1.29
Pre-travel health advice-seeking behavior among US international travelers departing from Boston Logan International Airport. J Travel Med (2010) 1.28
Anthropometrics and examiner-reported body habitus abnormalities in the multicenter AIDS cohort study. Clin Infect Dis (2004) 1.27
Use of total lymphocyte count and hemoglobin concentration for monitoring progression of HIV infection. J Acquir Immune Defic Syndr (2005) 1.24
Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals. Clin Vaccine Immunol (2007) 1.22
Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials (2011) 1.15
Adaptive interactions between HLA and HIV-1: highly divergent selection imposed by HLA class I molecules with common supertype motifs. J Immunol (2010) 1.15
Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142. HIV Clin Trials (2013) 0.99
CAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck. J Infect Dis (2012) 0.99
Translation of HLA-HIV associations to the cellular level: HIV adapts to inflate CD8 T cell responses against Nef and HLA-adapted variant epitopes. J Immunol (2011) 0.98
Rapid declines in total lymphocyte count and hemoglobin in HIV infection begin at CD4 lymphocyte counts that justify antiretroviral therapy. AIDS (2003) 0.98
Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study. J Acquir Immune Defic Syndr (2011) 0.97
Preservation HIV-1-specific IFNγ+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial. J Acquir Immune Defic Syndr (2012) 0.97
Anaemia in acute HIV-1 subtype C infection. PLoS One (2008) 0.96
Intentions to use preexposure prophylaxis among current phase 2B preventive HIV-1 vaccine efficacy trial participants. J Acquir Immune Defic Syndr (2013) 0.95
Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial. Antivir Ther (2012) 0.94
Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection. Clin Vaccine Immunol (2008) 0.94
Rapid declines in total lymphocyte counts and hemoglobin concentration prior to AIDS among HIV-1-infected men. AIDS (2003) 0.93
Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis. Clin Infect Dis (2013) 0.93
European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142. AIDS (2011) 0.93
Provider attitudes toward oral preexposure prophylaxis for HIV prevention among high-risk men who have sex with men in Lima, Peru. AIDS Res Hum Retroviruses (2014) 0.92
Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects. J Infect Dis (2011) 0.92
HIV prevention in high-risk women in South Africa: condom use and the need for change. PLoS One (2012) 0.91
HIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure prophylaxis trial. J Acquir Immune Defic Syndr (2015) 0.90
Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115. AIDS Res Hum Retroviruses (2009) 0.90
In pursuit of an HIV vaccine: designing efficacy trials in the context of partially effective nonvaccine prevention modalities. AIDS Res Hum Retroviruses (2013) 0.87
Recovery of replication-competent HIV type 1-infected circulating monocytes from individuals receiving antiretroviral therapy. AIDS Res Hum Retroviruses (2002) 0.86
A novel pattern of lipoaccumulation in HIV-infected men. JAMA (2006) 0.85
Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression. AIDS (2007) 0.84
A forgotten population: older adults with newly diagnosed HIV. AIDS Patient Care STDS (2014) 0.84
An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM. J Acquir Immune Defic Syndr (2017) 0.84
HIV serostatus disclosure is not associated with safer sexual behavior among HIV-positive men who have sex with men (MSM) and their partners at risk for infection in Bangkok, Thailand. AIDS Res Ther (2012) 0.83
Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study. J Acquir Immune Defic Syndr (2013) 0.82
Women with pregnancies had lower adherence to 1% tenofovir vaginal gel as HIV preexposure prophylaxis in CAPRISA 004, a phase IIB randomized-controlled trial. PLoS One (2013) 0.81
Peripheral neuropathy in ART-experienced patients: prevalence and risk factors. J Neurovirol (2013) 0.81
Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis. J Acquir Immune Defic Syndr (2016) 0.80
HIV vaccine-induced sero-reactivity: a challenge for trial participants, researchers, and physicians. Vaccine (2015) 0.80
Failure of initial therapy with two nucleosides and efavirenz is not associated with early emergence of mutations in the C-terminus of HIV-1 reverse transcriptase. J Acquir Immune Defic Syndr (2011) 0.79
Translational research insights from completed HIV vaccine efficacy trials. J Acquir Immune Defic Syndr (2013) 0.78
Factors associated with bone mineral density in healthy African women. Arch Osteoporos (2015) 0.77
Recruitment by a geospatial networking application for research and practice: the New York City experience. J Acquir Immune Defic Syndr (2014) 0.77
Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial data. Cost Eff Resour Alloc (2011) 0.75
The rise and fall of the AIDS Malignancy Consortium. Res Initiat Treat Action (2003) 0.75
Subclinical herpesvirus shedding among HIV-1-infected men on antiretroviral therapy. AIDS (2017) 0.75
Aching for a diagnosis. J Hosp Med (2010) 0.75
Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy. AIDS (2017) 0.75